Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension

Blood Pressure
Natali Ay ChungGregory Y H Lip

Abstract

Abnormalities in endothelial function, angiogenesis and thrombogenesis are found in essential hypertension. Angiotensin II has been postulated as an agent involved in these processes. We hypothesized that the treatment of essential hypertension with the angiotensin II receptor antagonist, losartan, would affect endothelial damage/dysfunction, angiogenesis and coagulation, when compared to treatment with a diuretic. Forty hypertensive patients (28 male, mean age 56 +/- 11.8 years) were randomized to treatment with losartan 50-100 mg o.d. or hydrochlorothiazide 12.5-25 mg o.d. over a 12-week period. Patients were assessed at week 0, 4 and 12. Endothelial damage/dysfunction was assessed using plasma levels of von Willebrand factor (vWf) and changes in flow-mediated dilation of the brachial artery (FMD). Vascular endothelial growth factor (VEGF) and its soluble receptor Flt-1 (sFlt-1) were measured as indices of angiogenesis, and plasma tissue factor (TF) as an index of coagulation. Baseline results in hypertensives were compared to 20 healthy controls (13 male, mean age 61.1 +/- 10.1 years). Mean patient BP was 161/95 +/- 21/18 mmHg compared to 134/81 +/- 11/7 mmHg in controls (p<0.002). Plasma levels of TF (p=0.023) were signific...Continue Reading

References

Dec 1, 1992·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·H A Struijker BoudierH van Essen
Jan 1, 1997·Thrombosis Research·P GalajdaP Kubisz
Mar 6, 1997·The American Journal of Cardiology·R J Cody
Apr 16, 1999·Hypertension·T F AntoniosG A MacGregor
Nov 1, 2001·Journal of Human Hypertension·P S SeverUNKNOWN ASCOT Steering Committee, Anglo-Scandinavian Cardiac Outcomes Trial
Jun 14, 2003·Journal of the Renin-angiotensin-aldosterone System : JRAAS·David G HarrisonKathy K Griendling

❮ Previous
Next ❯

Citations

Nov 1, 2005·Expert Opinion on Investigational Drugs·Dirk C Felmeden, Gregory Y H Lip
Jul 14, 2010·Clinical Biochemistry·Raffaele PalmirottaFiorella Guadagni
Nov 16, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Patrizia FerroniFiorella Guadagni
Apr 29, 2010·The Physician and Sportsmedicine·Leonardo P J Oliveira, Christine E Lawless
Feb 1, 2011·Respiratory Medicine·Vahid Mohsenin, Fred Urbano
Dec 31, 2005·Journal of Cardiovascular Pharmacology and Therapeutics·Giulia Dell'OmoRoberto Pedrinelli
Feb 5, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Annabella Braschi
Oct 11, 2008·The Journal of Physiological Sciences : JPS·Willmann LiangIsmail Laher
Jan 22, 2019·Current Medicinal Chemistry·Anastasios TentolourisNikolaos Tentolouris
Apr 6, 2021·Frontiers in Pharmacology·Yun CaiKeji Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.